- Home
- UA vs TVTX Comparison
UA vs TVTX Comparison
Compare UA & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UA | TVTX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | 14400 | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | UA | TVTX |
|---|---|---|
| Price | $5.95 | $26.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 02-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $44.62 |
| Revenue Next Year | $1.72 | $32.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.95 | $12.91 |
| 52 Week High | $7.91 | $42.13 |
Technical Indicators
Market Signals| Indicator | UA | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.60 | 38.47 |
| Support Level | $5.88 | $26.72 |
| Resistance Level | $6.43 | $31.47 |
| Average True Range (ATR) | 0.28 | 1.03 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 3.61 | 13.31 |
Price Performance
Historical ComparisonAbout UA Under Armour Inc. Class C
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.